If you are interested in learning more about this study, please call or email the contact person below
|Title||An Open-Label, Proof of Concept Study Designed to Evaluate the Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients with Newly Diagnosed, Moderate to Extensive Bullous Pemphigoid. Immune/BRT/BP-01|
|Description||Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid
Study visits will be in downtown, Buffalo.
|Objective||This is an open-label, proof-of-concept, single group study in adult patients with newly diagnosed, moderate to extensive Bullous Pemphigoid. The primary objective is to evaluate the safety of bertilimumab in patients with newly diagnosed, moderate to extensive BP.
Keywords: Bullous Pemphigoid, Bertilimumab, autoimmune
|Principal Investigator||SINHA, ANIMESH|
|Key Eligibility||Age 60 years or older
Newly diagnosed Bullous Pemphigoid
|Disease Group||Autoimmune Disorders; Skin/Dermatology|
|Treatment||Intravenous injection of Bertilimumab|